Welcome to BioSeeker Group!

Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Additional Information

Published Date Mar 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1103
PDF Fact Sheet View Fact Sheet for the report Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others.

    To find out more about Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report will excel your competitive awareness and decrease your decision making time in managing pancreatic cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer. BioSeeker has applied its unique drug assessment methodology to stratify the pancreatic cancer drug pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of pancreatic cancer drugs is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 37 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the pancreatic cancer drugs in general.

* Nine out of every ten drug target strategies in Phase III and Phase II development are new to pancreatic cancer drugs.

* The greatest number of new target strategies are found in Phase II (37%) and Phase I (18%) development.

* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of pancreatic cancer drugs, which represent almost 80% of the entire pipeline.

* Besides Reformulated drugs, it is Protein and Peptide based pancreatic cancer drugs that have the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies.

* The highest number of described drug target strategies of pancreatic cancer drugs belongs to Pfizer, Hoffmann-La Roche, Novartis and AstraZeneca.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any pancreatic cancer drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 19
4.2 List of Tables 19
5 Introduction 27
5.1 The Scope of this Report 27
5.2 Definitions 30
5.3 Abbreviations 30
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 31
6.1 Drug Repositioning in Oncology 31
6.2 Introduction to Targets of Pancreatic Cancer Drugs 32
6.2.1 Carboxy-lyase Activity Targets 39
6.2.2 Catalytic Activity Targets 40
6.2.3 Cell Adhesion Molecule Activity Targets 51
6.2.4 Chaperone Activity Targets 59
6.2.5 Cofactor Binding Targets 60
6.2.6 Cysteine-type Peptidase Activity Targets 62
6.2.7 Cytokine Activity Targets 69
6.2.8 DNA Binding Targets 75
6.2.9 DNA Repair Protein Targets 77
6.2.10 DNA Topoisomerase Activity Targets 80
6.2.11 DNA-directed DNA Polymerase Activity Targets 85
6.2.12 Extracellular Ligand-gated Ion Channel Activity Targets 92
6.2.13 Extracellular Matrix Structural Constituent Targets 94
6.2.14 G-protein Coupled Receptor Activity Targets 98
6.2.15 Growth Factor Activity Targets 108
6.2.16 GTPase Activity Targets 114
6.2.17 Hormone Activity Targets 123
6.2.18 Hydrolase Activity Targets 124
6.2.19 Ion Channel Activity Targets 125
6.2.20 Kinase Activity Targets 126
6.2.21 Kinase Binding Targets 138
6.2.22 Kinase Regulator Activity Targets 139
6.2.23 Ligand-dependent Nuclear Receptor Activity Targets 143
6.2.24 Ligase Activity Targets 144
6.2.25 Lipase activity 150
6.2.26 Lipid kinase activity 151
6.2.27 Lipid Phosphatase Activity Targets 154
6.2.28 Molecular Function Unknown Targets 155
6.2.29 Motor Activity Targets 165
6.2.30 Oxidoreductase Activity Targets 167
6.2.31 Peptidase Activity Targets 173
6.2.32 Peptide Hormone Targets 183
6.2.33 Peroxidase Activity Targets 185
6.2.34 Protein Binding Targets 186
6.2.35 Protein Serine/Threonine Kinase Activity Targets 188
6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 213
6.2.37 Protein Tyrosine Phosphatase Activity Targets 218
6.2.38 Protein-tyrosine Kinase Activity Targets 226
6.2.39 Receptor Activity Targets 237
6.2.40 Receptor Binding Targets 255
6.2.41 Receptor Signaling Complex Scaffold Activity Targets 260
6.2.42 RNA Binding Targets 264
6.2.43 RNA-directed DNA Polymerase Activity Targets 265
6.2.44 Serine-type Peptidase Activity Targets 266
6.2.45 Structural Constituent of Cytoskeleton Targets 271
6.2.46 Structural Molecule Activity Targets 273
6.2.47 Transcription Factor Activity Targets 274
6.2.48 Transcription Regulator Activity Targets 292
6.2.49 Transferase Activity Targets 298
6.2.50 Translation Regulator Activity Targets 299
6.2.51 Transmembrane Receptor Activity Targets 301
6.2.52 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 304
6.2.53 Transporter Activity Targets 340
6.2.54 Unclassified Targets 345
6.2.55 Voltage-gated Ion Channel Activity Targets 346
6.2.56 Other Targets 347
6.3 The Cancer Genome Project and Targets of Pancreatic Cancer Drugs 348
6.3.1 Targets of Pancreatic Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 348
6.4 Pancreatic Cancer Therapeutics is Stimulated by Available Structure Data on Targets 354
6.5 Target-Target Interactions among Identified Targets of Pancreatic Cancer Drugs 358
6.6 The Drug-Target Competitive Landscape 362
6.7 Protein Expression Levels of Identified Targets of Pancreatic Cancer Drugs 366
6.8 Pathway Assessment of Pancreatic Cancer Drugs 369
6.8.1 Tools for Analysis of Cancer Pathways 370
6.8.2 Pathway Assessment 371
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development 423
7.1 Registered to Marketed: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 425
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 426
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 428
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 433
7.5 Preclinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 436
7.6 Drug Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 438
7.7 Target Strategy Development Profiles of Pancreatic Cancer Drugs 440
7.7.1 Marketed 444
7.7.2 Phase III 447
7.7.3 Phase II 462
7.7.4 Phase I 522
7.7.5 Preclinical 552
7.7.6 Suspended 575
7.7.7 Ceased 577
7.8 The Competition Through Close Mechanistic Approximation of Pancreatic Cancer Drugs 609
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy 613
8.1 Small Molecules 615
8.1.1 Background 615
8.1.2 Target Strategies of Small Molecule Drugs 616
8.2 Peptide & Protein Drugs 624
8.2.1 Background 624
8.2.2 Target Strategies of Peptide and Protein Drugs 625
8.3 Antibodies 630
8.3.1 Background 630
8.3.2 Target Strategies of Antibody Drugs 630
8.4 Nucleic Acid Therapies 634
8.4.1 Background 634
8.4.2 Target Strategies of Nucleic Acid Drugs 635
8.5 Cell & Gene Therapy 637
8.5.1 Background 637
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 638
8.6 Drug Delivery and Nanotechnology 642
8.6.1 Background 642
8.6.2 Target Strategies of Reformulated Drugs 642
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 645
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator 652
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 656
9.2 Company Facts and Ranking 658
9.3 Competitive Fall-Out Assessment 666
9.4 AB Science 668
9.5 Abbott 670
9.6 Active Biotech 673
9.7 Advantagene 675
9.8 Advaxis 678
9.9 AEgera 681
9.10 Aida Pharmaceuticals 683
9.11 Amgen 685
9.12 Antisense Pharma 690
9.13 Anza Therapeutics 692
9.14 Apogee Biotechnology 694
9.15 Apotex 696
9.16 Ardea Biosciences 698
9.17 Ariad 701
9.18 ArQule 703
9.19 Array BioPharma 705
9.20 Astellas 709
9.21 AstraZeneca 714
9.22 AVEO 719
9.23 AVI BioPharma 721
9.24 Bayer 724
9.25 Betapharma 727
9.26 Biogen Idec 730
9.27 Bionovo 733
9.28 BioNumerik 735
9.29 BioSante 738
9.30 Boehringer Ingelheim 740
9.31 Bristol-Myers Squibb 742
9.32 BTG 747
9.33 Calando Pharmaceuticals 751
9.34 Cancer Advances 753
9.35 Cancer Research Technology 755
9.36 Celera 757
9.37 Celgene 759
9.38 Cell Therapeutics 763
9.39 Celldex Therapeutics 766
9.40 Celsion 769
9.41 Celtic Pharma 772
9.42 Center of Molecular Immunology 774
9.43 CG Therapeutics 777
9.44 CompleGen 780
9.45 Cornerstone Pharmaceuticals 782
9.46 CritiTech 784
9.47 Curaxis 787
9.48 Curis 789
9.49 Cyclacel 791
9.50 Cylene Pharmaceuticals 793
9.51 Cynvec 795
9.52 CytImmune Sciences 797
9.53 Cytokinetics 799
9.54 CytRx 801
9.55 Daiichi Sankyo 804
9.56 Dara Biosciences 809
9.57 EGEN Inc 811
9.58 Eisai 813
9.59 Eli Lilly 818
9.60 EntreMed 823
9.61 Epeius Biotechnologies 825
9.62 EpiCept 827
9.63 Esperance Pharmaceuticals 830
9.64 Exelixis 832
9.65 FibroGen 834
9.66 Galectin Therapeutics 836
9.67 Genta 839
9.68 GenVec 841
9.69 Geron 843
9.70 GlaxoSmithKline 845
9.71 GlycoGenesys 850
9.72 Hoffmann-La Roche 852
9.73 Human Genome Sciences 858
9.74 ImmunoCellular Therapeutics 860
9.75 ImmunoGen 862
9.76 Immunomedics 865
9.77 ImmuPharma 869
9.78 Immutep 871
9.79 Innate Pharma 873
9.80 Innovive 875
9.81 Insmed 878
9.82 Insys Therapeutics 881
9.83 Introgen Therapeutics 887
9.84 Ipsen 889
9.85 Johnson & Johnson 892
9.86 Kadmon 894
9.87 Kyowa Hakko Kirin 896
9.88 Leo 898
9.89 MBiotec 900
9.90 Meda 902
9.91 MediGene 904
9.92 Medisyn Technologies 908
9.93 Merck & Co 910
9.94 Merck KGaA 914
9.95 Merrimack 918
9.96 Mersana Therapeutics 921
9.97 MethylGene 924
9.98 Micromet 926
9.99 Nektar Therapeutics 928
9.100 Nereus Pharmaceuticals 931
9.101 Nippon Kayaku 933
9.102 Nippon Shinyaku 936
9.103 Non-industrial Source 938
9.104 Novacea 941
9.105 NovaLead 944
9.106 Novartis 947
9.107 Novogen 953
9.108 OncoMed 955
9.109 OncoTherapy Science 957
9.110 Oncothyreon 959
9.111 Oncozyme Pharma 961
9.112 Oxford BioMedica 963
9.113 OXiGENE 965
9.114 Paladin Labs 967
9.115 PanaGin 970
9.116 Patrys 972
9.117 Pepscan Therapeutics 974
9.118 Pfizer 976
9.119 Pharmacyclics 983
9.120 PharmaMar 985
9.121 Pharmexa 987
9.122 Pierre Fabre 990
9.123 Piramal 993
9.124 ProMetic Life Sciences 995
9.125 Protgen 997
9.126 Ras Therapeutics 999
9.127 Reata Pharmaceuticals 1001
9.128 Regeneron 1003
9.129 Regulon 1005
9.130 RESprotect 1007
9.131 Rexahn 1009
9.132 Rigel 1012
9.133 Rottapharm Madaus 1014
9.134 Samyang 1017
9.135 Sanofi 1021
9.136 Santaris Pharma 1026
9.137 Shire 1028
9.138 SuperGen 1030
9.139 Taiho 1034
9.140 Takeda 1038
9.141 Talon Therapeutics 1040
9.142 Tapestry Pharmaceuticals 1043
9.143 Tau Therapeutics 1046
9.144 Teva 1048
9.145 Thallion Pharmaceuticals 1050
9.146 Therion Biologics 1052
9.147 Titan Pharmaceuticals 1054
9.148 TopoTarget 1057
9.149 Tragara Pharmaceuticals 1060
9.150 Trion Pharma 1062
9.151 UMN Pharma 1064
9.152 VaxOnco 1066
9.153 Vertex Pharmaceuticals 1068
9.154 Vion Pharmaceuticals 1070
9.155 VioQuest 1072
9.156 ViroMed 1075
9.157 Wilex 1078
9.158 Xerion 1080
9.159 Yakult Honsha 1082
9.160 YM BioSciences 1085
9.161 Zeria 1088
Disclaimer 1090
10 Drug Index 1091
11 Company Index 1098

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 361
Figure 2: The Drug-Target Competitive Landscape of Pancreatic Cancer Drugs - Large Clusters 363
Figure 3: The Drug-Target Competitive Landscape Pancreatic Cancer Drugs - Smaller Clusters 364
Figure 4: Head-to-Head Targeting Competitive Landscape of Pancreatic Cancer Drugs 365
Figure 5: Distribution of Compound Strategies among Pancreatic Cancer Drugs 645
Figure 6: Primary Sub-cellular Localization of Drug Targets 646
Figure 7: Number of Companies per Ranking Level 661

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Pancreatic Cancer Drug Pipeline by Stage of Development 27
Table 3: Head to Head Target Competition among Pancreatic Cancer Drugs 27
Table 4: Overview of Drug Target Strategy Themes 32
Table 5: Terminally Ceased Targets of Pancreatic Cancer Drugs 33
Table 6: Official Gene Symbol to Target Profle 34
Table 7: Targets of Pancreatic Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 349
Table 8: Identity of Drug Targets with Available Biological Structures 354
Table 9: Number of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 359
Table 10: Available Protein Expression Profiles of Pancreatic Cancer Drug Targets 366
Table 11: Pathway Summary 371
Table 12: Drug Targets without any Identified Assigned Pathways 371
Table 13: Pathway Profiles According to BioCarta of Pancreatic Cancer Drug Targets 373
Table 14: Pathway Profiles According to KEGG of Pancreatic Cancer Drug Targets 392
Table 15: Pathway Profiles According to NetPath of Pancreatic Cancer Drug Targets 415
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 423
Table 17: Top Competitive Target Strategies of Pancreatic Cancer Drugs 424
Table 18: New and Unique Target Strategies of Registered and Marketed Pancreatic Cancer Drugs 425
Table 19: The Competition Through Close Mechanistic Approximation Between Pancreatic Cancer Drugs in Registered to Marketed 425
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Pancreatic Cancer Drugs 426
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Pancreatic Cancer Drugs 427
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Pancreatic Cancer Drugs 428
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Pancreatic Cancer Drugs 431
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Pancreatic Cancer Drugs 433
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Pancreatic Cancer Drugs 435
Table 26: New and Unique Target Strategies in Preclinical Development of Pancreatic Cancer Drugs 436
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Pancreatic Cancer Drugs 437
Table 28: Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 438
Table 29: Connecting Target Strategy with Its Profile Identification Number 440
Table 30: The Competition Through Close Mechanistic Approximation Among Pancreatic Cancer Drugs 609
Table 31: Overview of Compound Strategy Competition Among Pancreatic Cancer Drugs 614
Table 32: Overview of the Competitive Landscape of Small Molecule Based Pancreatic Cancer Drugs 616
Table 33: Competitive Comparison of Target Strategies of Small Molecule Pancreatic Cancer Drugs 617
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Pancreatic Cancer Drugs 619
Table 35: Overview of the Competitive Landscape of Peptide Based Pancreatic Cancer Drugs 625
Table 36: Competitive Comparison of Target Strategies of Peptide Based Pancreatic Cancer Drugs 626
Table 37: Pursued Target Strategies of Peptide Based Pancreatic Cancer Drugs 626
Table 38: Overview of the Competitive Landscape of Protein Based Pancreatic Cancer Drugs 628
Table 39: Pursued Target Strategies of Protein Based Pancreatic Cancer Drugs 629
Table 40: Overview of the Competitive Landscape of Antibody Based Pancreatic Cancer Drugs 630
Table 41: Competitive Comparison of Target Strategies of Antibody Based Pancreatic Cancer Drugs 631
Table 42: Pursued Target Strategies of Antibody Based Pancreatic Cancer Drugs 632
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Pancreatic Cancer Drugs 635
Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Pancreatic Cancer Drugs 636
Table 45: Pursued Target Strategies of Nucleic Acid Based Pancreatic Cancer Drugs 636
Table 46: Potential Forms of Cell Therapy 637
Table 47: Vectors in Gene Therapy 638
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Pancreatic Cancer Drugs 638
Table 49: Pursued Target Strategies of Cell Therapy Based Pancreatic Cancer Drugs 639
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Pancreatic Cancer Drugs 640
Table 51: Competitive Comparison of Target Strategies of Gene Therapy Based Pancreatic Cancer Drugs 641
Table 52: Pursued Target Strategies of Gene Therapy Based Pancreatic Cancer Drugs 641
Table 53:Overview of the Competitive Landscape of Reformulated Pancreatic Cancer Drugs 642
Table 54: Competitive Comparison of Target Strategies of Reformulated Pancreatic Cancer Drugs 643
Table 55: Pursued Target Strategies of Reformulated Pancreatic Cancer Drugs 644
Table 56: Compound Strategies based on Sub-Cellular Localization of Pancreatic Cancer Drug Targets 646
Table 57: Competitive Summary by Investigator of Pancreatic Cancer Drug Development 652
Table 58: Summary Table of Corporate Changes in the Competitive Landscape of Pancreatic Cancer Drug Development 656
Table 59: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 660
Table 60: Example of a Competitive Fall-Out Table (Targeting TYMS/Modified) 666
Table 61: AB Science’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 669
Table 62: Abbott’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 672
Table 63: Active Biotech’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 674
Table 64: Advantagene’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 677
Table 65: Advaxis’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 680
Table 66: AEgera’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 682
Table 67: Aida Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 684
Table 68: Amgen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 687
Table 69: Antisense Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 691
Table 70: Anza Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 693
Table 71: Apogee Biotechnology’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 695
Table 72: Apotex’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 697
Table 73: Ardea Biosciences’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 700
Table 74: Ariad’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 702
Table 75: ArQule’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 704
Table 76: Array BioPharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 707
Table 77: Astellas’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 711
Table 78: AstraZeneca’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 716
Table 79: AVEO’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 720
Table 80: AVI BioPharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 723
Table 81: Bayer’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 725
Table 82: Betapharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 729
Table 83: Biogen Idec’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 732
Table 84: Bionovo’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 734
Table 85: BioNumerik’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 737
Table 86: BioSante’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 739
Table 87: Boehringer Ingelheim’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 741
Table 88: Bristol-Myers Squibb’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 744
Table 89: BTG’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 749
Table 90: Calando Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 752
Table 91: Cancer Advances’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 754
Table 92: Cancer Research Technology’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 756
Table 93: Celera’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 758
Table 94: Celgene’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 761
Table 95: Cell Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 765
Table 96: Celldex Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 768
Table 97: Celsion’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 771
Table 98: Celtic Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 773
Table 99: Center of Molecular Immunology’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 776
Table 100: CG Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 779
Table 101: CompleGen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 781
Table 102: Cornerstone Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 783
Table 103: CritiTech’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 786
Table 104: Curaxis’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 788
Table 105: Curis’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 790
Table 106: Cyclacel’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 792
Table 107: Cylene Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 794
Table 108: Cynvec’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 796
Table 109: CytImmune Sciences’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 798
Table 110: Cytokinetics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 800
Table 111: CytRx’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 803
Table 112: Daiichi Sankyo’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 807
Table 113: Dara Biosciences’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 810
Table 114: EGEN Inc’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 812
Table 115: Eisai’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 815
Table 116: Eli Lilly’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 820
Table 117: EntreMed’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 824
Table 118: Epeius Biotechnologies’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 826
Table 119: EpiCept’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 829
Table 120: Esperance Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 831
Table 121: Exelixis’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 833
Table 122: FibroGen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 835
Table 123: Galectin Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 838
Table 124: Genta’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 840
Table 125: GenVec’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 842
Table 126: Geron’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 844
Table 127: GlaxoSmithKline’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 847
Table 128: GlycoGenesys’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 851
Table 129: Hoffmann-La Roche’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 854
Table 130: Human Genome Sciences’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 859
Table 131: ImmunoCellular Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 861
Table 132: ImmunoGen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 864
Table 133: Immunomedics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 867
Table 134: ImmuPharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 870
Table 135: Immutep’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 872
Table 136: Innate Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 874
Table 137: Innovive’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 877
Table 138: Insmed’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 880
Table 139: Insys Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 884
Table 140: Introgen Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 888
Table 141: Ipsen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 891
Table 142: Johnson & Johnson’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 893
Table 143: Kadmon’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 895
Table 144: Kyowa Hakko Kirin’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 897
Table 145: Leo’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 899
Table 146: MBiotec’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 901
Table 147: Meda’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 903
Table 148: MediGene’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 906
Table 149: Medisyn Technologies’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 909
Table 150: Merck & Co’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 912
Table 151: Merck KGaA’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 916
Table 152: Merrimack’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 920
Table 153: Mersana Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 923
Table 154: MethylGene’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 925
Table 155: Micromet’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 927
Table 156: Nektar Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 930
Table 157: Nereus Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 932
Table 158: Nippon Kayaku’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 935
Table 159: Nippon Shinyaku’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 937
Table 160: Non-industrial source’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 940
Table 161: Novacea’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 943
Table 162: NovaLead’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 946
Table 163: Novartis’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 949
Table 164: Novogen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 954
Table 165: OncoMed’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 956
Table 166: OncoTherapy Science’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 958
Table 167: Oncothyreon’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 960
Table 168: Oncozyme Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 962
Table 169: Oxford BioMedica’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 964
Table 170: OXiGENE’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 966
Table 171: Paladin Labs’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 969
Table 172: PanaGin’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 971
Table 173: Patrys’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 973
Table 174: Pepscan Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 975
Table 175: Pfizer’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 978
Table 176: Pharmacyclics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 984
Table 177: PharmaMar’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 986
Table 178: Pharmexa’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 989
Table 179: Pierre Fabre’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 992
Table 180: Piramal’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 994
Table 181: ProMetic Life Sciences’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 996
Table 182: Protgen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 998
Table 183: Ras Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1000
Table 184: Reata Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1002
Table 185: Regeneron’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1004
Table 186: Regulon’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1006
Table 187: RESprotect’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1008
Table 188: Rexahn’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1011
Table 189: Rigel’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1013
Table 190: Rottapharm Madaus’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1016
Table 191: Samyang’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1019
Table 192: Sanofi’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1023
Table 193: Santaris Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1027
Table 194: Shire’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1029
Table 195: SuperGen’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1032
Table 196: Taiho’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1036
Table 197: Takeda’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1039
Table 198: Talon Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1042
Table 199: Tapestry Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1045
Table 200: Tau Therapeutics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1047
Table 201: Teva’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1049
Table 202: Thallion Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1051
Table 203: Therion Biologics’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1053
Table 204: Titan Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1056
Table 205: TopoTarget’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1059
Table 206: Tragara Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1061
Table 207: Trion Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1063
Table 208: UMN Pharma’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1065
Table 209: VaxOnco’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1067
Table 210: Vertex Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1069
Table 211: Vion Pharmaceuticals’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1071
Table 212: VioQuest’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1074
Table 213: ViroMed’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1077
Table 214: Wilex’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1079
Table 215: Xerion’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1081
Table 216: Yakult Honsha’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1084
Table 217: YM BioSciences’ Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1087
Table 218: Zeria’s Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1089

This report includes 158 companies (Incl. Out of Business ones) plus their collaborators:
AB Science
Abbott
Active Biotech
Advantagene
Advaxis
AEgera
Aida Pharmaceuticals
Amgen
Antisense Pharma
Anza Therapeutics
Apogee Biotechnology
Apotex
Ardea Biosciences
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
AVEO
AVI BioPharma
Bayer
Betapharma
Biogen Idec
Bionovo
BioNumerik
BioSante
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Research Technology
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
CompleGen
Cornerstone Pharmaceuticals
CritiTech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dara Biosciences
EGEN Inc
Eisai
Eli Lilly
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Exelixis
FibroGen
Galectin Therapeutics
Genta
GenVec
Geron
GlaxoSmithKline
GlycoGenesys
Hoffmann-La Roche
Human Genome Sciences
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Innate Pharma
Innovive
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
Johnson & Johnson
Kadmon
Kyowa Hakko Kirin
Leo
MBiotec
Meda
MediGene
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Nektar Therapeutics
Nereus Pharmaceuticals
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
OncoMed
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaMar
Pharmexa
Pierre Fabre
Piramal
ProMetic Life Sciences
Protgen
Ras Therapeutics
Reata Pharmaceuticals
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Shire
SuperGen
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Titan Pharmaceuticals
TopoTarget
Tragara Pharmaceuticals
Trion Pharma
UMN Pharma
VaxOnco
Vertex Pharmaceuticals
Vion Pharmaceuticals
VioQuest
ViroMed
Wilex
Xerion
Yakult Honsha
YM BioSciences
Zeria
This report includes 247 pancreatic cancer drugs. From Ceased to Marketed. Some examples are:
AEG-35156
aflibercept
AGS-1C4D4
apricoxib
ARC-100
ARQ-197
bardoxolone methyl
bevacizumab
bosutinib
brivanib alaninate
brivudine
Cabozantinib
capecitabine
catumaxomab
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
CRLX-101
dalotuzumab
dasatinib
docetaxel
doxorubicin
E-7820
eniluracil
enzastaurin hydrochloride
erlotinib
everolimus
ganitumab
gefitinib
GSK-1120212
GV-1001
GVAX
icotinib hydrochloride
imatinib mesilate
IMP-321
ipilimumab
irinotecan
irinotecan hydrochloride
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
LipoVIL12
masitinib
MetXia
MKC-1
mocetinostat
motexafin gadolinium
nadroparin
nimotuzumab
oblimersen sodium
olaparib
OTS-102
P-276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
plitidepsin
polyclonal antibody stimulator
PX-12
Rexin-G
romidepsin
RX-0201
selumetinib
siltuximab
sorafenib tosylate
ß-lapachone
sunitinib malate
talminogene laherparepvec
tegafur + uracil
temsirolimus
tigatuzumab
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
varlitinib
vismodegib
volociximab
WX-671
yttrium Y 90 clivatuzumab tetraxetan
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others.
    To find out more about Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Breast Cancer - Therapeutic And Competitive Insights
Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy. Learn More


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More

Other selected research from the 'Oncology' category:


Gastrointestinal Cancer Drug Pathway Analyzer
There are today at least 292 targeted molecular therapies known to affect more than 241 specific intracellular signaling pathways for the treatment of gastrointestinal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 174 drug targets that are included in this drug-pathway analyzing tool. No less than 167 of these have been recorded with mutations and 45 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lymphoma, Pancreatic Cancer and Prostate Cancer. Learn More